Epidemiology-based risk assessment using the benchmark dose/margin of exposure approach: The example of ethanol and liver cirrhosis

International Journal of Epidemiology

Volumn 40, Issue 1, 2011, Pages 210-218

  Lachenmeier, Dirk W ^a   Kanteres, Fotis ^b,c   Rehm, Jürgen ^b,d,e  

^a Chemisches und Veterinaruntersuchungsamt CVUA Karlsruhe   (Germany)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Alcohol; Alcoholic beverages; Benchmark dose; Dose response relationship; Epidemiological methods; Ethanol; Liver cirrhosis; Margin of exposure; Risk assessment

Indexed keywords

ALCOHOL; BENCHMARKING; DIGESTIVE SYSTEM DISORDER; DOSE-RESPONSE RELATIONSHIP; EPIDEMIOLOGY; ETHANOL; HEALTH POLICY; MORTALITY; PUBLIC HEALTH; RISK ASSESSMENT;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ARTICLE; COHORT ANALYSIS; DRINKING BEHAVIOR; FEMALE; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

BENCHMARKING; CANADA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; RISK ASSESSMENT; RISK FACTORS;

EID: 79952060839     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyq150     Document Type: Article

References (65)

1. Hoffmeister H, Schelp FP, Mensink GB, Dietz E, Böhning D. The relationship between alcohol consumption, health indicators and mortality in the German population. Int J Epidemiol 1999;28: 1066-72.
2. Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: the scientific evidence. Can J Public Health 1999;90:264-70.
3. Rehm J, Room R, Taylor B. Method for moderation: measuring lifetime risk of alcohol-attributable mortality as a basis for drinking guidelines. Int J Methods Psychiatr Res 2008;17:141-51.
4. Burger M, Brönstrup A, Pietrzik K. Derivation of tolerable upper alcohol intake levels in Germany: a systematic review of risks and benefits of moderate alcohol consumption. Prev Med 2004;39:111-27.
5. Victorin K, Haag-Grönlund M, Skerfving S. Methods for health risk assessment of chemicals: are they relevant for alcohol? Alcohol Clin Exp Res 1998;22:270S-6S.
6. Rydberg U, Skerfving S. The toxicity of ethanol. A tentative risk evaluation. Adv Exp Med Biol 1977;85B:403-19.
7. Gmel G, Rehm J. Measuring alcohol consumption. Contemp Drug Probl 2004;31:467-540.
8. Harding R, Stockley CS. Communicating through government agencies. Ann Epidemiol 2007;17:S98-102.
9. Rehm J, Ashley MJ, Room R et al. On the emerging paradigm of drinking patterns and their social and health consequences. Addiction 1996;91:1615-21.
10. Baan R, Straif K, Grosse Y et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007;8:292-3.
11. Hamajima N, Hirose K, Tajima K et al. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-45.
12. Rehm J, Baliunas D, Borges GLG et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 2010;105: 817-43.
13. Bi J. Using the Benchmark Dose (BMD) Methodology to determine an appropriate reduction of certain ingredients in food products. J Food Sci 2010;75:R9-16.
14. Crump KS. A new method for determining allowable daily intakes. Fundam Appl Toxicol 1984;4:854-71.
15. US EPA. The Use of the Benchmark Dose Approach in Health Risk Assessment. EPA/630/R-94/007. Washington, DC: Office of Research and Development. US Environmental Protection Agency, 1995.
16. EFSA. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA J 2005;282:1-31.
17. Muri SD, Schlatter JR, Brüschweiler BJ. The benchmark dose approach in food risk assessment: is it applicable and worthwhile? Food Chem Toxicol 2009;47:2906-25.
18. Castorina R, Woodruff TJ. Assessment of potential risk levels associated with U.S. environmental protection agency reference values. Environ Health Perspect 2003; 111:1318-25.
19. Sand S, Victorin K, Filipsson AF. The current state of knowledge on the use of the benchmark dose concept in risk assessment. J Appl Toxicol 2008;28:405-21.
20. Filipsson AF, Sand S, Nilsson J, Victorin K. The benchmark dose method - review of available models, and recommendations for application in health risk assessment. Crit Rev Toxicol 2003;33:505-42.
21. Benford D, Bolger PM, Carthew P et al. Application of the margin of exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem Toxicol 2010;48:S2-24.
22. Budtz-Jørgensen E, Keiding N, Grandjean P. Benchmark dose calculation from epidemiological data. Biometrics 2001;57:698-706.
23. Budtz-Jørgensen E, Grandjean P, Keiding N, White RF, Weihe P. Benchmark dose calculations of methylmercury-associated neurobehavioural deficits. Toxicol Lett 2000; 112-113:193-99.
24. Crump KS, Van Landingham C, Shamlaye C et al. Benchmark concentrations for methylmercury obtained from the Seychelles Child Development Study. Environ Health Perspect 2000;108:257-63.
25. Morales KH, Ryan LM. Benchmark dose estimation based on epidemiologic cohort data. Environmetrics 2005;16: 435-47.
26. Morales KH, Ibrahim JG, Chen CJ, Ryan LM. Bayesian model averaging with applications to benchmark dose estimation for arsenic in drinking water. J Am Stat Assoc 2006;101:9-17.
27. Jin T, Wu X, Tang Y et al. Environmental epidemiological study and estimation of benchmark dose for renal dysfunction in a cadmium-polluted area in China. Biometals 2004;17:525-30.
28. Goldbohm RA, Tielemans EL, Heederik D et al. Risk estimation for carcinogens based on epidemio-logical data: a structured approach, illustrated by an example on chromium. Regul Toxicol Pharmacol 2006;44: 294-310.
29. Lin T, Xiao-Ting L, Ai G, Qiu-Ying L, Tai-Yi J. Application of benchmark dose for occupational epidemiology in lead exposure. Toxicol Mech Methods 2008;18:363-67.
30. Crump KS, Teeguarden JG. Benchmark calculations from summarized data: an example. Environ Ecol Stat 2009;16: 13-24.
31. Bailer AJ, Stayner LT, Smith RJ, Kuempel ED, Prince MM. Estimating benchmark concentrations and other non-cancer endpoints in epidemiology studies. Risk Anal 1997; 17:771-80.
32. Dakeishi M, Iwata T, Ishii N, Murata K. Effects of alcohol consumption on hepatocellular injury in Japanese men. Tohoku J Exp Med 2004;202:31-39.
33. Dakeishi M, Murata K, Tamura A, Iwata T. Relation between benchmark dose and no-observed-adverse-effect level in clinical research: effects of daily alcohol intake on blood pressure in Japanese salesmen. Risk Anal 2006;26: 115-23.
34. Lachenmeier DW, Kanteres F, Kuballa T, López MG, Rehm J. Ethyl Carbamate in Alcoholic Beverages from Mexico (Tequila, Mezcal, Bacanora, Sotol) and Guatemala (Cuxa): Market Survey and Risk Assessment. Int J Environ Res Public Health 2009;6:349-60.
35. Lachenmeier DW, Kanteres F, Rehm J. Carcinogenicity of acetaldehyde in alcoholic beverages: risk assessment outside ethanol metabolism. Addiction 2009;104:533-50.
36. EFSA. Ethyl carbamate and hydrocyanic acid in food and beverages. EFSA J 2007;551:1-44.
37. Lachenmeier DW, Lima MC, Nobrega IC et al. Cancer risk assessment of ethyl carbamate in alcoholic beverages from Brazil with special consideration to the spirits cachaca and tiquira. BMC Cancer 2010;10:266.
38. Gold LS, Ames BN, Slone TH. How Many Fold Lower is Human Exposure than the Dose that Gave Rodents Cancer: Margin of Exposure, MOE (Rodent Cancer Dose/Human Exposure). Berkeley, CA: Carcinogenic Potency Project, University of California, Berkeley, 2008. http://potency.berkeley.edu/MOEtable.html. Archived by WebCite® at http://www.webcitation.org/5ix20tFMx (1 September 2010, date last accessed).
39. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223-33.
40. Rehm J, Taylor B, Mohapatra S et al. Alcohol as a risk factor for liver cirrhosis - a systematic review and meta-analysis. Drug Alcohol Rev 2010;29:437-45.
41. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 96, Alcoholic Beverage Consumption and Ethyl Carbamate (Urethane). Lyon, France: IARC; in press.
42. Watabiki T, Okii Y, Tokiyasu T et al. Long-term ethanol consumption in ICR mice causes mammary tumor in females and liver fibrosis in males. Alcohol Clin Exp Res 2000;24:117S-22S.
43. Yokoyama H, Nagata S, Moriya S et al. Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts. Hepatology 1995;21:1438-42.
44. Keegan A, Martini R, Batey R. Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. J Hepatol 1995;23:591-600.
45. French SW, Wong K, Jui L, Albano E, Hagbjork AL, Ingelman-Sundberg M. Effect of ethanol on cytochrome P450 2E1 (CYP2E1), lipid peroxidation, and serum protein adduct formation in relation to liver pathology pathogenesis. Exp Mol Pathol 1993;58:61-75.
46. French SW, Miyamoto K, Tsukamoto H. Ethanol-induced hepatic fibrosis in the rat: role of the amount of dietary fat. Alcohol Clin Exp Res 1986;10:13S-9S.
47. Soffritti M, Belpoggi F, Cevolani D, Guarino M, Padovani M, Maltoni C. Results of long-term experimental studies on the carcinogenicity of methyl alcohol and ethyl alcohol in rats. Ann N Y Acad Sci 2002;982: 46-69.
48. NTP technical report on the toxicology and carcinogensis. Studies of urethane, ethanol, and urethane/ethanol (urethane, CAS No. 51-79-6; ethanol, CAS No. 64-17-5) in B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser 2004;510:1-346.
49. Beland FA, Benson RW, Mellick PW, Kovatch RM, Roberts DW, Fang JL et al. Effect of ethanol on the tumorigenicity of urethane (ethyl carbamate) in B6C3F1 mice. Food Chem Toxicol 2005;43:1-19.
50. WHO. Global Information System on Alcohol and Health. Geneva, Switzerland. http://www.who.int/globalatlas/default.asp. World Health Organization, 2009 (1 September 2010, date last accessed).
51. Rehm J, Rehn N, Room R et al. The global distribution of average volume of alcohol consumption and patterns of drinking. Eur Addict Res 2003;9:147-56.
52. Rehm J, Room R, Monteiro M et al. Alcohol use. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL (eds). Comparative Quantification of Health Risks. Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Vol. 1. Geneva: World Health Organization, 2004, pp. 959-1108.
53. Rehm J, Klotsche J, Patra J. Comparative quantification of alcohol exposure as risk factor for global burden of disease. Int J Methods Psychiatr Res 2007;16: 66-76.
54. CAMH. Low-Risk Drinking Guidelines [pamphlet]. Toronto, Canada: Centre for Addiction and Mental Health, 2005.
55. IPCS. Environmental Health Criteria 239: Principles for Modelling Dose-Response for the Risk Assessment of Chemicals. Geneva: World Health Organization, 2009.
56. IPCS. Environmental Health Criteria 70: Principles for the Safety Assessment of Food Additives and Contaminants in Food. Geneva: World Health Organization, 1987.
57. Sanner T, Dybing E. Comparison of carcinogen hazard characterisation based on animal studies and epidemiology. Basic Clin Pharmacol Toxicol 2005;96:66-70.
58. Sillanaukee P, Massot N, Jousilahti P et al. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol 2000;152:747-51.
59. Lachenmeier DW, Rehm J. Unrecorded alcohol: a threat to public health? Addiction 2009;104:875-77.
60. Babor T, Caetano R, Casswell S et al. Alcohol: No Ordinary Commodity. Research and Public Policy. 2nd edn. Oxford, UK: Oxford University Press, 2010.
61. Khan AJ, Husain Q, Choudhuri G, Parmar D. Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Drug Alcohol Depend 2010;109:190-97.
62. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydro-genase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004;63:49-63.
63. Druesne-Pecollo N, Tehard B, Mallet Y et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009;10:173-80.
64. Husemoen LL, Fenger M, Friedrich N, Tolstrup JS, Beenfeldt FS, Linneberg A. The association of ADH and ALDH gene variants with alcohol drinking habits and cardiovascular disease risk factors. Alcohol Clin Exp Res 2008;32:1984-91.
65. Vermeire T, Stevenson H, Peiters MN, Rennen M, Slob W, Hakkert BC. Assessment factors for human health risk assessment: a discussion paper. Crit Rev Toxicol 1999;29: 439-90.